Show simple item record

dc.contributor.authorMartínez Rubio, Álvaro 
dc.contributor.authorChulián, Salvador
dc.contributor.authorBlázquez Goñi, Cristina
dc.contributor.authorRamírez-Orellana, Manuel
dc.contributor.authorPérez Martínez, Antonio
dc.contributor.authorNavarro Zapata, Alfonso
dc.contributor.authorFerreras, Cristina
dc.contributor.authorPérez-García, Víctor M.
dc.contributor.authorRosa Durán, María 
dc.contributor.otherMatemáticases_ES
dc.date.accessioned2021-09-20T10:45:30Z
dc.date.available2021-09-20T10:45:30Z
dc.date.issued2021-06
dc.identifier.issn1422-0067
dc.identifier.urihttp://hdl.handle.net/10498/25459
dc.description.abstractChimeric Antigen Receptor (CAR) T-cell therapy has demonstrated high rates of response in recurrent B-cell Acute Lymphoblastic Leukemia in children and young adults. Despite this success, a fraction of patients' experience relapse after treatment. Relapse is often preceded by recovery of healthy B cells, which suggests loss or dysfunction of CAR T-cells in bone marrow. This site is harder to access, and thus is not monitored as frequently as peripheral blood. Understanding the interplay between B cells, leukemic cells, and CAR T-cells in bone marrow is paramount in ascertaining the causes of lack of response. In this paper, we put forward a mathematical model representing the interaction between constantly renewing B cells, CAR T-cells, and leukemic cells in the bone marrow. Our model accounts for the maturation dynamics of B cells and incorporates effector and memory CAR T-cells. The model provides a plausible description of the dynamics of the various cellular compartments in bone marrow after CAR T infusion. After exploration of the parameter space, we found that the dynamics of CAR T product and disease were independent of the dose injected, initial B-cell load, and leukemia burden. We also show theoretically the importance of CAR T product attributes in determining therapy outcome, and have studied a variety of possible response scenarios, including second dosage schemes. We conclude by setting out ideas for the refinement of the model.es_ES
dc.description.sponsorshipThis work was partially supported by the Fundacion Espanola para la Ciencia y la Tecnologia (UCA PR214), the Asociacion Pablo Ugarte (APU, Spain), Junta de Comunidades de Castilla-La Mancha (SBPLY/17/180501/000154), Ministry of Science and Technology, Spain (PID2019110895RB-I00), and Inversion Territorial Integrada de la Provincia de Cadiz (ITI-0038-2019).es_ES
dc.formatapplication/pdfes_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.sourceInt. J. Mol. Sci. 2021, 22(12), 6371es_ES
dc.subjectCAR Tes_ES
dc.subjectmathematical modeles_ES
dc.subjectacute lymphoblastic leukemiaes_ES
dc.subjectB celles_ES
dc.subjectbone marrowes_ES
dc.titleA Mathematical Description of the Bone Marrow Dynamics during CAR T-Cell Therapy in B-Cell Childhood Acute Lymphoblastic Leukemiaes_ES
dc.typejournal articlees_ES
dc.rights.accessRightsopen accesses_ES
dc.identifier.doi10.3390/ijms22126371
dc.relation.projectIDinfo:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020/PID2019-110895RB-I00/ES/MODELOS MATEMATICOS EN ONCOLOGIA/es_ES


Files in this item

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
This work is under a Creative Commons License Atribución 4.0 Internacional